Dr. Roué on Interest With TG-1701 in Ibrutinib-Resistant MCL Models


Gaël Roué, PhD, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma.

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses interest regarding the novel irreversible inhibitor TG-1701 in models of ibrutinib (Imbruvica)-resistant mantle cell lymphoma (MCL).

A study presented at the 2020 AACR Virtual Meeting tested the activity of TG-1701 when combined with ublituximab and umbralisib in ibrutinib-resistant MCL. Interest in TG-1701 comes from the fact that there is a large interest regarding BTK inhibitors for B-cell malignancies, says Roué. This is due to the fact that most first- or second-generation molecules have nonspecific activity but could impact other signals within the tumor B-cells. This molecule draws a lot of interest within the MCL space as it is more specific to the BTK pathway, explains Roué.

Another point of interest is that when investigators compared the second-generation molecule with the first-in-class inhibitor, ibrutinib, they found that some activity was retained in cases of resistance to ibrutinib, concludes Roué.

Related Videos
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Rita Nanda, MD
Vikram Narayan, MD
Daniel Olson, MD
Vishal Patel, MD, FAAD, FACMS, associate professor, Dermatology, George Washington (GW) School of Medicine & Health Sciences
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute